Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M G Princen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
European Journal of Clinical Nutrition|May 29, 2003
Safety of long-term consumption of plant sterol esters-enriched spreadH F J Hendriks, E J Brink, G W Meijer, et al.
Atherosclerosis|December 17, 2002
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitusM A van de Ree, M V Huisman, H M G Princen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 29, 2006
Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterolT Kooistra, L Verschuren, J de Vries-van der Weij, et al.
Journal of Thrombosis and Haemostasis : JTH|August 13, 2003
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitusM A Van De Ree, M P M De Maat, C Kluft, et al.
British Journal of Pharmacology|February 18, 2009
The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic miceJ W A van der Hoorn, J W Jukema, L M Havekes, et al.
European Journal of Human Genetics : EJHG|July 9, 2004
Modulating effect of the A-278C promoter polymorphism in the cholesterol 7alpha-hydroxylase gene on serum lipid levels in normolipidaemic and hypertriglyceridaemic individualsM K Hofman, M Groenendijk, P J J H Verkuijlen, et al.
Annals of the Rheumatic Diseases|April 30, 2013
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosisL M Gierman, S Kühnast, A Koudijs, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 28, 2005
No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic miceA Trion, M P M de Maat, J W Jukema, et al.
Osteoarthritis and Cartilage|November 28, 2022
IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse modelY van Gemert, N N L Kruisbergen, A B Blom, et al.
Diabetes, Obesity & Metabolism|December 31, 2013
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndromeA M van den Hoek, J W A van der Hoorn, A C Maas, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
European Journal of Clinical Nutrition|May 29, 2003
Safety of long-term consumption of plant sterol esters-enriched spreadH F J Hendriks, E J Brink, G W Meijer, et al.
Atherosclerosis|December 17, 2002
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitusM A van de Ree, M V Huisman, H M G Princen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 29, 2006
Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterolT Kooistra, L Verschuren, J de Vries-van der Weij, et al.
Journal of Thrombosis and Haemostasis : JTH|August 13, 2003
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitusM A Van De Ree, M P M De Maat, C Kluft, et al.
British Journal of Pharmacology|February 18, 2009
The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic miceJ W A van der Hoorn, J W Jukema, L M Havekes, et al.
European Journal of Human Genetics : EJHG|July 9, 2004
Modulating effect of the A-278C promoter polymorphism in the cholesterol 7alpha-hydroxylase gene on serum lipid levels in normolipidaemic and hypertriglyceridaemic individualsM K Hofman, M Groenendijk, P J J H Verkuijlen, et al.
Annals of the Rheumatic Diseases|April 30, 2013
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosisL M Gierman, S Kühnast, A Koudijs, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 28, 2005
No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic miceA Trion, M P M de Maat, J W Jukema, et al.
Osteoarthritis and Cartilage|November 28, 2022
IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse modelY van Gemert, N N L Kruisbergen, A B Blom, et al.
Diabetes, Obesity & Metabolism|December 31, 2013
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndromeA M van den Hoek, J W A van der Hoorn, A C Maas, et al.
Pageof 2